Loading...
Currently available oral antiviral agents for the treatment of chronic hepatitis B virus (HBV) infection are effective in suppressing viral infection but rarely lead to clearance of infection. Therapies are needed that increase the rate of durable response and lead to long-term hepatitis B surface antigen (HBsAg)–positive inactive carrier states or to HBsAg-negative or HBsAg-negative/hepatitis B surface antibody (HBsAb)–positive states.
In an industry-sponsored, phase I, proof-of-concept study, researchers assessed anti-HBV activity and safety of NVR 3-778, a novel HBV capsid assembly modulator. They enrolled 73 hepatitis B e antigen (HBeAg)–positive, HBV-infected patients without cirrhosis. Patients were randomized to receive NVR 3-778 once…